Lilly, Zepbound and weight loss
Digest more
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug ...
Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...
Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...
Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...
In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...
Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback